Skip to main content
. 2023 Sep 14;13(11):2394–2411. doi: 10.1158/2159-8290.CD-23-0436

Figure 5.

Figure 5. ctDNA dynamics as surrogate for response. Patients with MPR are indicated in closed teal circle; patients without MPR are indicated in open gray circle. Top left: mean VAF at baseline is compared between patients with an MPR and with no MPR across all arms. Top right: mean VAF at baseline associated across stage I, II, or III disease. Bottom left: mean VAF at baseline correlated with the sum of diameters among target lesions at baseline (mm) (total patients with ctDNA evaluable at baseline N = 33; durvalumab monotherapy arm: n = 13; durvalumab + oleclumab arm: n = 11; durvalumab + monalizumab arm: n = 9). Bottom right: for patients with detectable ctDNA at baseline (total N = 20; durvalumab monotherapy arm: n = 6; durvalumab + oleclumab arm: n = 7, durvalumab + monalizumab arm: n = 7), molecular response (≥50% reduction in VAF from baseline) is depicted at end of treatment (EOT; day 28) and follow-up (FU; day 105) time points for all patients with evaluable ctDNA at those time points (N are depicted above). W1D1, week 1, day 1.

ctDNA dynamics as surrogate for response. Patients with MPR are indicated in closed teal circle; patients without MPR are indicated in open gray circle. Top left: mean VAF at baseline is compared between patients with an MPR and with no MPR across all arms. Top right: mean VAF at baseline associated across stage I, II, or III disease. Bottom left: mean VAF at baseline correlated with the sum of diameters among target lesions at baseline (mm) (total patients with ctDNA evaluable at baseline N = 33; durvalumab monotherapy arm: n = 13; durvalumab + oleclumab arm: n = 11; durvalumab + monalizumab arm: n = 9). Bottom right: for patients with detectable ctDNA at baseline (total N = 20; durvalumab monotherapy arm: n = 6; durvalumab + oleclumab arm: n = 7, durvalumab + monalizumab arm: n = 7), molecular response (≥50% reduction in VAF from baseline) is depicted at end of treatment (EOT; day 28) and follow-up (FU; day 105) time points for all patients with evaluable ctDNA at those time points (N are depicted above). W1D1, week 1, day 1.